Clinical Trial Update: Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update examining the effect of food on AZD9291 (osimertinib) blood levels in patients with advanced non-small cell lung cancer; study completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2016-04-05